|
Dr. Goddard was appointed Chief Executive Officer of OSI in October 1998. He served as the Company’s President from September 1997 to September 2000; Executive Vice President and Chief Operating Officer from September 1996 to September 1997; Vice President, Research Operations from April 1995 to September 1996; Vice President, Research Operations, Pharmaceutical Division from December 1993 to April 1995; Director, Pharmaceutical Operations from April 1993 to December 1993; Director, Drug Discovery from April 1992 to April 1993; and Program Manager, Drug Discovery from April 1991 to April 1992. Dr. Goddard joined the Corporation as a scientist in January 1989. Dr. Goddard also served as Chairman of the Board from 2000 to 2002. Dr. Goddard has been a director of the company since October 1998.
Dr. Colin Goddard has led the transition of OSI from a technology platform services company into today’s profitable fully integrated biopharmaceutical organization. Dr. Goddard’s leadership and vision were instrumental in the approval and launch of the Company’s flagship product Tarceva® (erlotinib). Dr. Goddard has also led the Company’s corporate development, acquisition and financing efforts in recent years, completing multiple major acquisitions and divestitures and raising over $1.2 billion in capital.
Dr. Goddard is active in many organizations which promote the advancement of cancer treatment and awareness, science education and the biotechnology industry, including: Board of the Biotechnology Industry Association (BIO), and Gilda’s Club (New York). He is a member of the American Association of Cancer Research. Before joining the Corporation, Dr. Goddard spent four years at the National Cancer Institute in Bethesda, Maryland. Dr. Goddard also serves on the board of Zelos Therapeutics, a private biotechnology company focused on osteoporosis. Dr. Goddard trained as a cancer pharmacologist in Birmingham, U.K. and received his Ph.D. from the University of Aston, Birmingham, U.K. in September 1985. He was honored as a D.Sc. from the State University of New York in 2003 and Hofstra University in 2005. | 